Phaseline

Companies › Akyso Therapeutics

Akyso Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Psychiatry; next expected readout Oct 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Naltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 1Opioid Use DisorderOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07064564NaltrexonePhase 1Opioid Use DisorderPsychiatryOct 2029
NCT07064564NaltrexonePhase 1Opioid Use DisorderPsychiatryOct 2029

Targets

OPRK1 (1) OPRD1 (1) OPRM1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Johnson & Johnson (Janssen) Tioga Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.